CTMX Документы SEC - CytomX Therapeutics, Inc.- Годовой отчет, доверенное заявление, проспект эмиссии

Основная статистика

LEI	5493004VW2FW0QLL3345
CIK	1501989

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to CytomX Therapeutics, Inc.

SEC Filings (Chronological Order)

На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.

August 13, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2025 CytomX Therapeuti UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2025 CytomX Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37587 27-3521219 (State or Other Jurisdiction of Incorporation) (Commissi
August 7, 2025	S-8	As filed with the Securities and Exchange Commission on August 7, 2025 S-8 As filed with the Securities and Exchange Commission on August 7, 2025 Registration No.
August 7, 2025	EX-10.2	Amended and Restated CytomX Therapeutics, Inc. Employee Stock Purchase Plan. CYTOMX THERAPEUTICS, INC. AMENDED AND RESTATED EMPLOYEE STOCK PURCHASE PLAN 1. Purpose. The purpose of this Plan is to provide Employees of the Company and Participating Subsidiaries with an opportunity to purchase common stock of the Company through accumulated payroll deductions. It is the intention of the Company to have the Plan qualify as an “Employee Stock Purchase Plan” under Section 423 of
August 7, 2025	EX-99.1	CytomX Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update - May 12, 2025 announcement of positive interim data from ongoing Phase 1 study of CX-2051 (EpCAM Antibody Drug Conjugate) in patients with advanced colo Exhibit 99.1 CytomX Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update - May 12, 2025 announcement of positive interim data from ongoing Phase 1 study of CX-2051 (EpCAM Antibody Drug Conjugate) in patients with advanced colorectal cancer (CRC) - - CX-2051 Phase 1 dose expansions on track for data update in Q1 2026. Phase 2 study initiation in CRC anticipated
August 7, 2025	EX-FILING FEES	Filing Fee Table. Calculation of Filing Fee Tables S-8 CytomX Therapeutics, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, par value $0.00001 per share Other 4,381,320 $ 2.29 $ 10,033,222.80 0.0001531 $ 1,536.09 Tota
August 7, 2025	EX-FILING FEES	Filing Fee Table. Calculation of Filing Fee Tables S-3 CytomX Therapeutics, Inc. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward I
August 7, 2025	EX-4.7	Form of Indenture. EX-4.7 Exhibit 4.7 CytomX Therapeutics, Inc. INDENTURE Dated as of [], 20[] [] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 4 Section 1.3. Incorporation by Reference of Trust Indenture Act 4 Section 1.4. Rules of Construction 5 ARTICLE II. THE SECURITIES 5 Section 2.1. Issuable in Series 5 Sectio
August 7, 2025	S-3	As filed with the Securities and Exchange Commission on August 7, 2025 S-3 Table of Contents As filed with the Securities and Exchange Commission on August 7, 2025 Registration No.
August 7, 2025	8-K	FORM 8-K Item 2.02 Results of Operations and Financial Condition. Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 07, 2025 CytomX Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37587 27-3521219 (State or Other Jurisdiction of Incorporation) (Commissi
August 7, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37587 CytomX Ther
June 13, 2025	EX-10.1	Amended and Restated CytomX Therapeutics, Inc. 2015 Equity Incentive Plan EX-10.1 Exhibit 10.1 CYTOMX THERAPEUTICS, INC. AMENDED AND RESTATED 2015 EQUITY INCENTIVE PLAN Adopted by Board: September 17, 2015 Approved by Stockholders: October 2, 2015 Amended and Restated: March 19, 2025 I. INTRODUCTION 1.1 Purposes. This CytomX Therapeutics, Inc. Amended and Restated 2015 Equity Incentive Plan as set forth herein (this “Plan”) amends, restates and supersedes the CytomX The
June 13, 2025	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2025 CytomX Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37587 27-3521219 (State or Other Jurisdiction of Incorporation) (Commission
June 13, 2025	EX-10.2	Amended and Restated CytomX Therapeutics, Inc. Employee Stock Purchase Plan EX-10.2 Exhibit 10.2 CYTOMX THERAPEUTICS, INC. AMENDED AND RESTATED EMPLOYEE STOCK PURCHASE PLAN 1. Purpose. The purpose of this Plan is to provide Employees of the Company and Participating Subsidiaries with an opportunity to purchase common stock of the Company through accumulated payroll deductions. It is the intention of the Company to have the Plan qualify as an “Employee Stock Purchase Plan”
May 28, 2025	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2025 CYTOMX THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37587 27-3521219 (State or Other Jurisdiction of Incorporation) (Commission
May 13, 2025	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2025 CYTOMX THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37587 27-3521219 (State or Other Jurisdiction of Incorporation) (Commission
May 13, 2025	EX-1.1	Underwriting Agreement, dated as of May 12, 2025, among CytomX Therapeutics, Inc. and Jefferies LLC and Piper Sandler & Co., as representatives of the several underwriters named therein. Exhibit 1.1 Execution Version CytomX Therapeutics, Inc. 76,923,076 Shares of Common Stock $0.00001 par value Underwriting Agreement May 12, 2025 Jefferies LLC Piper Sandler & Co. As representatives (the “Representatives”) of the several Underwriters named in Schedule I hereto c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 c/o Piper Sandler & Co. 800 Nicollet Mall, Suite 800 Minneapo
May 12, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2025 CYTOMX THERAPEUTICS, UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2025 CYTOMX THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37587 27-3521219 (State or Other Jurisdiction of Incorporation) (Commission
May 12, 2025	424B5	76,923,076 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-281433 PROSPECTUS SUPPLEMENT (To Prospectus dated August 9, 2024) 76,923,076 Shares of Common Stock We are offering 76,923,076 shares of our common stock, par value $0.00001 per share, pursuant to this prospectus supplement and the accompanying prospectus. Our common stock is listed on The Nasdaq Global Select Market under the
May 12, 2025	EX-99.1	CytomX Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update - Announced Positive Interim Data From Ongoing Phase 1 Dose Escalation Study of EpCAM Antibody Drug Conjugate (CX-2051) in Patients with Advanced Colorect Exhibit 99.1 CytomX Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update - Announced Positive Interim Data From Ongoing Phase 1 Dose Escalation Study of EpCAM Antibody Drug Conjugate (CX-2051) in Patients with Advanced Colorectal Cancer (CRC) - - Initiated CX-2051 Phase 1 dose expansions at 7.2 mg/kg, 8.6 mg/kg, and 10 mg/kg doses. Additional CX-2051 Phase 1 dat
May 12, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37587 CytomX The
May 12, 2025	EX-10.1	Separation Agreement, dated January 30, 2025, by and between CytomX Therapeutics, Inc. and Jeffrey Landau. Exhibit 10.1 SEPARATION AGREEMENT This Separation Agreement (the “Agreement”) by and between Jeffrey Landau (“Executive”), and CytomX Therapeutics, Inc., a Delaware corporation (the “Company”), is made effective as of the eighth (8th) day following the date Executive signs this Agreement if not revoked in accordance with Section 5(c)(iii) (the “Effective Date”) with reference to the following fact
April 28, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rul
April 28, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only
March 6, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 06, 2025 CytomX Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37587 27-3521219 (State or Other Jurisdiction of Incorporation) (Commissio
March 6, 2025	EX-FILING FEES	Filing Fee Table Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) CytomX Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Plan Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Share (2) Maximum Aggregate Offering Price Fee Rate Amount of registration fee CytomX Therapeu
March 6, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37587 CytomX Therapeu
March 6, 2025	EX-99.1	CytomX Therapeutics Announces 2024 Financial Results and Provides Business Update - Continued progress with lead program, CX-2051 (EpCAM PROBODY® Topo-1 ADC), in Phase 1a study in advanced colorectal cancer with initial Phase 1a clinical data to be p Exhibit 99.1 CytomX Therapeutics Announces 2024 Financial Results and Provides Business Update - Continued progress with lead program, CX-2051 (EpCAM PROBODY® Topo-1 ADC), in Phase 1a study in advanced colorectal cancer with initial Phase 1a clinical data to be presented in 1H 2025 - - CX-801 (PROBODY® Interferon-alpha 2b) Phase 1a translational data in advanced melanoma expected in 2H 2025 - - Ma
March 6, 2025	S-8	Power of Attorney. Reference is made to the signature page to the Registration Statement. As filed with the Securities and Exchange Commission on March 6, 2025 Registration No.
February 26, 2025	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2025 CYTOMX THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37587 27-3521219 (State or Other Jurisdiction of Incorporation) (Commis
February 3, 2025	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2025 CYTOMX THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37587 27-3521219 (State or Other Jurisdiction of Incorporation) (Commiss
January 6, 2025	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2025 CYTOMX THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37587 27-3521219 (State or Other Jurisdiction of Incorporation) (Commissi
November 14, 2024	SC 13G/A	CTMX / CytomX Therapeutics, Inc. / Cormorant Asset Management, LP Passive Investment SC 13G/A 1 cormorant-ctmx093024a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* CytomX Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 23284F105 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to
November 14, 2024	SC 13G/A	CTMX / CytomX Therapeutics, Inc. / BIOTECHNOLOGY VALUE FUND L P - AMENDMENT NO. 3 TO SCHEDULE 13G Passive Investment SC 13G/A 1 sc13ga307422ctmx11142024.htm AMENDMENT NO. 3 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 3)1 CytomX Therapeutics, Inc. (Name of Issuer) Common Stock, $0.00001
November 14, 2024	SC 13G/A	CTMX / CytomX Therapeutics, Inc. / TANG CAPITAL MANAGEMENT LLC - AMENDMENT NO.3 Passive Investment SC 13G/A 1 ctmx1015241sc13ga3.htm AMENDMENT NO.3 Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3) * CytomX Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 23284F105 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Statement) C
November 14, 2024	EX-99.1	JOINT FILING AGREEMENT EX-99.1 2 ex991.htm EXHIBIT 99.1 Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, $0.00001 par value per share, of CytomX Therapeutics, Inc. and further agree to the filing
November 7, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 07, 2024 CytomX Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37587 27-3521219 (State or Other Jurisdiction of Incorporation) (Commis
November 7, 2024	EX-99.1	CytomX Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - Phase 1a dose escalation for CX-904 (EGFR-CD3 PROBODY® T-cell engager) continues to advance. Potential Phase 1b initiation in 2025. - - Phase 1 study of C Exhibit 99.1 CytomX Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - Phase 1a dose escalation for CX-904 (EGFR-CD3 PROBODY® T-cell engager) continues to advance. Potential Phase 1b initiation in 2025. - - Phase 1 study of CX-2051 (EpCAM PROBODY® ADC) in advanced colorectal cancer (CRC) is currently in the fifth dose escalation cohort. Initial data anticipate
November 7, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37587 CytomX
August 15, 2024	CORRESP	CytomX Therapeutics, Inc. 151 Oyster Point Blvd., Suite 400 South San Francisco, CA 94080 CytomX Therapeutics, Inc. 151 Oyster Point Blvd., Suite 400 South San Francisco, CA 94080 August 15, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Tamika Sheppard Re: CytomX Therapeutics, Inc. Registration Statement on Form S-3 (Registration No. 333-281433) Ladies and Gentlemen: In accordance with Rule 461 of R
August 9, 2024	EX-1.4	Amendment No. 2 to Open Market Sales Agreement, dated as of August 9, 2024, by and between CytomX Therapeutics, Inc. and Jefferies LLC. Exhibit 1.4 AMENDMENT NO. 2 TO THE OPEN MARKET SALE AGREEMENT August 9, 2024 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: This Amendment No. 2 to the Open Market Sale Agreement (this “Amendment”) is entered into as of the date first written above by CytomX Therapeutics, Inc., a Delaware corporation (the “Company”), and Jefferies LLC (the “Agent”), that are partie
August 9, 2024	EX-1.3	Amendment No. 1 to Open Market Sales Agreement, dated as of March 4, 2022, by and between CytomX Therapeutics, Inc. and Jefferies LLC Exhibit 1.3 AMENDMENT NO. 1 TO THE OPEN MARKET SALE AGREEMENT March 4, 2022 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: This Amendment No. 1 to the Open Market Sale Agreement (this “Amendment”) is entered into as of the date first written above by CytomX Therapeutics, Inc., a Delaware corporation (the “Company”), and Jefferies LLC (the “Agent”), that are parties
August 9, 2024	EX-4.5	Form of Indenture. Exhibit 4.5 CytomX Therapeutics, Inc. INDENTURE Dated as of [], 20[] [] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 4 Section 1.3. Incorporation by Reference of Trust Indenture Act 5 Section 1.4. Rules of Construction 5 ARTICLE II. THE SECURITIES 5 Section 2.1. Issuable in Series 5 Section 2.2. Est
August 9, 2024	EX-FILING FEES	Filing Fee Table. Exhibit 107.1 Calculation of Filing Fee Table Form S-3 (Form Type) CytomX Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registratio
August 9, 2024	S-3	As filed with the Securities and Exchange Commission on August 9, 2024 Table of Contents As filed with the Securities and Exchange Commission on August 9, 2024 Registration No.
August 8, 2024	EX-10.1	Amendment No.1 to the Collaboration and License Agreement effective as of June 28, 2024 by and between CytomX Therapeutics, Inc. and Regeneron Pharmaceuticals, Inc. Exhibit 10.1 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) may be competitively harmful if publicly disclosed. Amendment No. 1 to the Collaboration and License Agreement This Amendment No. 1 (“Amendment”) to the Collaboration and License Agreement effective November 16, 2022 (“Agreement”) by and between CytomX Therapeutics, Inc., hav
August 8, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37587 CytomX Ther
August 8, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 08, 2024 CytomX Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37587 27-3521219 (State or Other Jurisdiction of Incorporation) (Commissi
August 8, 2024	EX-99.1	CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update - CX-904 (EGFR-CD3 PROBODY® T-cell engager) Phase 1a enrollment continues, primarily focused in PDAC, NSCLC, and HNSCC. Program update expected by the end Exhibit 99.1 CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update - CX-904 (EGFR-CD3 PROBODY® T-cell engager) Phase 1a enrollment continues, primarily focused in PDAC, NSCLC, and HNSCC. Program update expected by the end of 2024 - - Phase 1 clinical study of CX-2051, an EpCAM targeting PROBODY® ADC, is ongoing. Study is currently enrolling third cohort wit
June 17, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2024 CytomX Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37587 27-3521219 (State or Other Jurisdiction of Incorporation) (Commission
May 17, 2024	EX-3.1	Amended and Restated Certificate of Incorporation of CytomX Therapeutics, Inc. Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CYTOMX THERAPEUTICS, INC. (a Delaware corporation) (Pursuant to Sections 228, 242 and 245 of the General Corporation Law of the State of Delaware) CytomX Therapeutics, Inc., a corporation organized and existing under the General Corporation Law of the State of Delaware as set forth in Title 8 of the Delaware Code (the “DGCL”), hereby
May 17, 2024	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2024 CytomX Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37587 27-3521219 (State or Other Jurisdiction of Incorporation) (Commission
May 13, 2024	SC 13G	CTMX / CytomX Therapeutics, Inc. / Cormorant Asset Management, LP Passive Investment SC 13G 1 sc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* CytomX Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 23284F105 (CUSIP Number) May 2, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant
May 13, 2024	EX-99.1	JOINT FILING AGREEMENT EX-99.1 2 exhibit99-1.htm JOINT FILING AGREEMENT BY AND AMONG THE REPORTING PERSONS Exhibit 99.1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of May 13, 2024, is by and among Cormorant Global Healthcare Master Fund, LP, Cormorant Global Healthcare GP, LLC, Cormorant Asset Management, LP and Bihua Chen (collectively, the “Filers”). Each of the Filers may be required to file with the
May 8, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37587 CytomX The
May 8, 2024	EX-10.1	Amendment No. 4 to the Collaboration and License Agreement, dated as of March 28, 2024, by and between CytomX Therapeutics, Inc. and Amgen, Inc. DocuSign Envelope ID: BC0B85A8-4C4E-49BF-9DC2-0D8965BBCF25 Exhibit 10.1 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) may be competitively harmful if publicly disclosed. AMENDMENT NO. 4 TO THE COLLABORATION AND LICENSE AGREEMENT This Amendment No. 4 to the Collaboration Agreement (this “Amendment”) is effective as of the 28th day of
May 8, 2024	EX-99.1	CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager) - CX-904 demonstrated a favorable safety profile with no cytokine release syndrome (CRS) of any grade observed in s Exhibit 99.1 CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager) - CX-904 demonstrated a favorable safety profile with no cytokine release syndrome (CRS) of any grade observed in step-dosing cohorts and no grade >1 CRS observed overall - - Encouraging initial signs of efficacy observed for CX-904 in advanced pancrea
May 8, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 08, 2024 CytomX Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37587 27-3521219 (State or Other Jurisdiction of Incorporation) (Commission
May 8, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2024 CytomX Therapeutics, UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2024 CytomX Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37587 27-3521219 (State or Other Jurisdiction of Incorporation) (Commission F
May 8, 2024	EX-99.1	CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update - Company announces positive initial Phase 1a dose escalation data for monotherapy CX-904 (EGFRxCD3 T-cell engager) in solid tumors - - First dose cohort cl Exhibit 99.1 CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update - Company announces positive initial Phase 1a dose escalation data for monotherapy CX-904 (EGFRxCD3 T-cell engager) in solid tumors - - First dose cohort cleared in Phase 1 clinical study of CX-2051, an EpCAM Targeting PROBODY® ADC, in solid tumors. Initial data anticipated in the first half
May 1, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi
April 4, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rul
April 4, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ D
March 25, 2024	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule
March 22, 2024	EX-3.1	Amended and Restated Bylaws of CytomX Therapeutics, Inc., effective March 20, 2024. Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF CYTOMX THERAPEUTICS, INC. (A DELAWARE CORPORATION) ARTICLE I OFFICES Section 1. Registered Office. The registered office of CytomX Therapeutics, Inc. (the “Corporation”) in the State of Delaware shall be as set forth in the Certificate of Incorporation of the Corporation, as amended from time to time (the “Certificate of Incorporation”). Section 2. Other
March 22, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2024 CytomX Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37587 27-3521219 (State or Other Jurisdiction of Incorporation) (Commissio
March 11, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37587 CytomX Therapeu
March 11, 2024	EX-19.1	Corporate Securities Trading Policy Corporate Policy Document No: CORP-003 Revision: 1.0 Effective Date: 30 December 2019 Title: Securities Trading Exhibit 19.1 Purpose: CytomX Therapeutics, Inc. (“CytomX” or “Company”) is committed to establishing rules and guidelines for all employees, directors, consultants and contractors that require compliance with all applicable laws with respect to their trading of securities of CytomX and o
March 11, 2024	EX-99.1	CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update - CX-904 (EGFRxCD3 T-cell engager) initial Phase 1a dose escalation data in solid tumors anticipated in the 2nd half of 2024 - - CX-2051 (EpCAM ADC) Phase 1 clinical stud Exhibit 99.1 CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update - CX-904 (EGFRxCD3 T-cell engager) initial Phase 1a dose escalation data in solid tumors anticipated in the 2nd half of 2024 - - CX-2051 (EpCAM ADC) Phase 1 clinical study initiation in solid tumors, including colorectal cancer (CRC) anticipated in the 1st half of 2024 - - CX-801 (IFNα2b) Phase 1 clinical
March 11, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) CytomX Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Plan Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Share (2) Maximum Aggregate Offering Price Fee Rate Amount of registration fee CytomX Therape
March 11, 2024	EX-97.1	Executive Compensation Clawback Policy Corporate Policy Document No: CORP-018 Revision: 1.0 Effective Date: December 1, 2023 Executive Compensation Clawback Policy Exhibit 97.1 PURPOSE: CytomX Therapeutics, Inc. (the “Company”) has adopted this Executive Compensation Clawback Policy (the “Policy”) for recovery of Erroneously Awarded Compensation effective as of December 1, 2023 (the “Effective Date”). Capitalized terms used in this P
March 11, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2024 CytomX Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37587 27-3521219 (State or Other Jurisdiction of Incorporation) (Commissio
March 11, 2024	S-8	As filed with the Securities and Exchange Commission on March 11, 2024 As filed with the Securities and Exchange Commission on March 11, 2024 Registration No.
February 14, 2024	SC 13G/A	CTMX / CytomX Therapeutics, Inc. / TANG CAPITAL PARTNERS LP - AMENDMENT NO. 2 Passive Investment Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.
February 14, 2024	SC 13G/A	CTMX / CytomX Therapeutics, Inc. / BIOTECHNOLOGY VALUE FUND L P - AMENDMENT NO. 2 TO SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2)1 CytomX Therapeutics, Inc. (Name of Issuer) Common Stock, $0.00001 par value per share (Title of Class of Securities) 23284F105 (CUSIP Numb
February 13, 2024	SC 13G/A	CTMX / CytomX Therapeutics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0727-cytomxtherapeuticsinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: CytomX Therapeutics Inc Title of Class of Securities: Common Stock CUSIP Number: 23284F105 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to
November 7, 2023	EX-99.1	CytomX Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update - CX-904 (EGFRxCD3 T-cell engager) initial Phase 1 dose escalation data anticipated in the first half of 2024 - - CX-2051 (EpCAM-directed ADC) comprehensive Exhibit 99.1 CytomX Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update - CX-904 (EGFRxCD3 T-cell engager) initial Phase 1 dose escalation data anticipated in the first half of 2024 - - CX-2051 (EpCAM-directed ADC) comprehensive preclinical profile presented at 14th Annual World ADC Conference; IND filing on track for year-end - - Updated CX-801 (conditionally ac
November 7, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 07, 2023 CytomX Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37587 27-3521219 (State or Other Jurisdiction of Incorporation) (Commis
November 7, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37587 CytomX Therapeutics, Inc. (Exact name of
November 7, 2023	EX-10.1	Transition Agreement effective as of August 22, 2023 by and between CytomX Therapeutics, Inc., and AbbVie Global Enterprises Ltd. Execution Copy Exhibit 10.1 TRANSITION AGREEMENT This Transition Agreement (this “Transition Agreement”), effective as of the date fully executed by the Parties (the “Transition Effective Date”), is by and among AbbVie Global Enterprises Ltd., a Bermuda corporation (“AbbVie”), and CytomX Therapeutics Inc., a Delaware corporation with offices at 151 Oyster Point Boulevard, Suite 400, South San Fran
August 28, 2023	424B3	25,961,539 Shares Common Stock Offered by the Selling Securityholders Table of Contents As Filed Pursuant to Rule 424(b)(3) Registration No. 333-274010 PROSPECTUS 25,961,539 Shares Common Stock Offered by the Selling Securityholders This prospectus relates to the resale from time to time of up to 25,961,539 shares of our common stock, $0.00001 par value per share, by the selling securityholders identified in this prospectus (collectively with any donees, pledgees, t
August 24, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 08, 2023 CytomX Therapeuti UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 08, 2023 CytomX Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37587 27-3521219 (State or Other Jurisdiction of Incorporation) (Commissi
August 23, 2023	CORRESP	CytomX Therapeutics, Inc. 151 Oyster Point Blvd., Suite 400 South San Francisco, California 94080 CytomX Therapeutics, Inc. 151 Oyster Point Blvd., Suite 400 South San Francisco, California 94080 August 23, 2023 Via EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Jimmy McNamara Re: CytomX Therapeutics, Inc. Registration Statement on Form S-3 Filed August 16, 2023 Registration No.
August 16, 2023	S-3	As filed with the Securities and Exchange Commission on August 15, 2023 Table of Contents As filed with the Securities and Exchange Commission on August 15, 2023 Registration No.
August 16, 2023	EX-FILING FEES	Filing Fee Table. Exhibit 107.1 Calculation of Filing Fee Table Registration Statement on Form S-3 (Form Type) CytomX Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price(2)
August 8, 2023	EX-10.2	Form of Amended and Restated Severance and Change of Control Agreement by and between CytomX Therapeutics, Inc. and each of its executive officers other than Sean A. McCarthy. Exhibit 10.2 Amended and Restated Severance and Change of Control Agreement This Amended and Restated Severance and Change of Control Agreement (the “Agreement”) is made and entered into, effective as of [ ] (the “Effective Date”), by and between CytomX Therapeutics, Inc. a Delaware corporation (the “Company”), and [ ] (“Employee”). Upon acceptance of this Agreement, the following terms and condit
August 8, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 08, 2023 CytomX Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37587 27-3521219 (State or Other Jurisdiction of Incorporation) (Commissi
August 8, 2023	EX-99.1	CytomX Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update - CX-904 (EGFRxCD3) initial Phase 1 dose escalation data anticipated first half of 2024 - - IND filings for CX-2051 (EpCAM-directed ADC) and CX-801 (Interf Exhibit 99.1 CytomX Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update - CX-904 (EGFRxCD3) initial Phase 1 dose escalation data anticipated first half of 2024 - - IND filings for CX-2051 (EpCAM-directed ADC) and CX-801 (Interferon alpha-2b) anticipated in the fourth quarter of 2023 - - Management to hold conference call today at 5 p.m. EDT / 2 p.m. PDT - SOUTH
August 8, 2023	EX-10.1	Amendment No. 3 to the Collaboration and License Agreement, dated as of May 18, 2023, by and between CytomX Therapeutics, Inc. and Amgen, Inc. Exhibit 10.1 AMENDMENT NO. 3 TO THE COLLABORATION AND LICENSE AGREEMENT This Amendment No. 3 to the Collaboration Agreement (this “Amendment”) is effective as of the 18th day of May, 2023 (the “Amendment Effective Date”) by and between Amgen Inc., a Delaware corporation having an address at One Amgen Center Drive, Thousand Oaks, California 91320 (“Amgen”) and CytomX Therapeutics, Inc., a Delaware
August 8, 2023	EX-10.3	Employment Offer Letter Agreement between CytomX Therapeutics, Inc. and Jeffrey Landau dated as of March 31, 2021. Exhibit 10.3 SENT VIA DOCUSIGN March 13, 2021 Jeff Landau [email protected] Dear Jeff, On behalf of Cytomx Therapeutics (“CytomX” or the “Company”), I am pleased to offer you an exempt position of Senior Vice President, Chief Business Officer, and Head of Strategy Development, reporting to Sean McCarthy, D. Phil., President, Chief Executive Officer and Chairman. Total Rewards: Compensation Y
August 8, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37587 CytomX Therapeutics, Inc. (Exact name of Regi
July 3, 2023	EX-4.1	Form of Pre-Funded Warrant EX-4.1 Exhibit 4.1 THE SECURITIES REPRESENTED HEREBY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES OR IN ANY OTHER JURISDICTION. THE HOLDER MAY NOT OFFER, SELL, TRANSFER, ASSIGN, PLEDGE, HYPOTHECATE, OR OTHERWISE DISPOSE OF OR ENCUMB
July 3, 2023	EX-10.1	Unit Purchase Agreement by and among the CytomX Therapeutics, Inc. and certain accredited investors named therein, dated June 29, 2023. EX-10.1 Exhibit 10.1 UNIT PURCHASE AGREEMENT This Unit Purchase Agreement (this “Agreement”) is dated as of June 29, 2023, by and among CytomX Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditio
July 3, 2023	EX-4.2	Form of Tranche Warrant EX-4.2 Exhibit 4.2 THE SECURITIES REPRESENTED HEREBY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES OR IN ANY OTHER JURISDICTION. THE HOLDER MAY NOT OFFER, SELL, TRANSFER, ASSIGN, PLEDGE, HYPOTHECATE, OR OTHERWISE DISPOSE OF OR ENCUMB
July 3, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2023 CYTOMX THERAPEUTICS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2023 CYTOMX THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37587 27-3521219 (State or Other Jurisdiction of Incorporation) (Commission
June 20, 2023	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2023 CYTOMX THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37587 27-3521219 (State or Other Jurisdiction of Incorporation) (Commission
May 9, 2023	EX-10	Sublease Agreement dated as of March 24, 2023, by and between CytomX Therapeutics, Inc and Atomic AI, Inc. Exhibit 10.1 SUBLEASE THIS SUBLEASE (this “Sublease”) is dated for reference purposes as of March 24, 2023, and is made by and between CytomX Therapeutics, Inc., a Delaware corporation (“Sublessor”), and Atomic AI, Inc., a Delaware corporation (“Sublessee”). Sublessor and Sublessee hereby agree as follows: 1. Recitals: This Sublease is made with reference to the fact that HCP Oyster Point Ill LLC,
May 9, 2023	EX-99	CytomX Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update - Continued progress in Phase 1 dose escalation for CX-904 (EGFRxCD3) - - IND enabling activities on track for filings for CX-2051 (EpCAM-directed ADC) and Exhibit 99.1 CytomX Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update - Continued progress in Phase 1 dose escalation for CX-904 (EGFRxCD3) - - IND enabling activities on track for filings for CX-2051 (EpCAM-directed ADC) and CX-801 (Interferon alpha-2b) in the second half of 2023 - - Bristol Myers Squibb advances Anti-CTLA-4 non-fucosylated Probody®, BMS-98628
May 9, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 09, 2023 CytomX Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37587 27-3521219 (State or Other Jurisdiction of Incorporation) (Commission
May 9, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37587 CytomX Therapeutics, Inc. (Exact name of Reg
April 27, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule
April 27, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Def
March 27, 2023	S-8	As filed with the Securities and Exchange Commission on March 27, 2023 S-8 As filed with the Securities and Exchange Commission on March 27, 2023 Registration No.
March 27, 2023	EX-10	Collaboration and License Agreement dated as of November 16, 2022 by and between CytomX Therapeutics, Inc. and Regeneron Pharmaceuticals, Inc. Exhibit 10.24 COLLABORATION AND LICENSE AGREEMENT by and between CYTOMX THERAPEUTICS, inc. and REGENERON PHARMACEUTICALS, INC. Dated as of November 16, 2022 Execution Version COLLABORATION AND LICENSE AGREEMENT This Collaboration and License Agreement (“Agreement”) is entered into as of November 16, 2022 (the “Effective Date”) by and between CytomX Therapeutics, Inc., organized and existing under
March 27, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2023 CytomX Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37587 27-3521219 (State or Other Jurisdiction of Incorporation) (Commissio
March 27, 2023	EX-10	Collaboration and License Agreement dated as of December 30, 2022 by and between CytomX Therapeutics, Inc. and ModernaTX, Inc. CONFIDENTIAL EXECUTION VERSION Exhibit 10.25 COLLABORATION AND LICENSE AGREEMENT by and between CYTOMX THERAPEUTICS, inc. and MODERNATX, INC. Dated as of December 30, 2022 CONFIDENTIAL EXECUTION VERSION COLLABORATION AND LICENSE AGREEMENT This Collaboration and License Agreement (“Agreement”) is entered into as of December 30, 2022 (the “Effective Date”) by and between CytomX Therapeutics, Inc., o
March 27, 2023	EX-FILING FEES	Filing Fee Table EX-FILING FEES Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) CytomX Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Plan Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Share (3) Maximum Aggregate Offering Price Fee Rate Amount of registration fee C
March 27, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37587 CytomX Therapeu
March 27, 2023	EX-99	CytomX Therapeutics Reports Full Year 2022 Financial Results and Provides Business Update - Internal focus on next generation therapeutic pipeline including ongoing Phase 1 for CX-904 (EGFRxCD3) and anticipated IND filings for CX-2051 (EpCAM-directed Exhibit 99.1 CytomX Therapeutics Reports Full Year 2022 Financial Results and Provides Business Update - Internal focus on next generation therapeutic pipeline including ongoing Phase 1 for CX-904 (EGFRxCD3) and anticipated IND filings for CX-2051 (EpCAM-directed ADC) and CX-801 (Interferon alpha-2b) in the second half of 2023 - - Bristol Myers Squibb advances Anti-CTLA-4 non-fucosylated Probody®,
March 27, 2023	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37587 CytomX Therap
March 10, 2023	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 CYTOMX THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37587 27-3521219 (State or Other Jurisdiction of Incorporation) (Commissio
February 24, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2023 CYTOMX THERAPEU UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2023 CYTOMX THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37587 27-3521219 (State or Other Jurisdiction of Incorporation) (Commis
February 14, 2023	SC 13G/A	CTMX / CytomX Therapeutics Inc / Point72 Asset Management, L.P. - SCHEDULE 13G/A, AMENDMENT #2 Passive Investment 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* (Name of Issuer) CytomX Therapeutics, Inc. (Title of Class of Securities) Common Stock, par value $0.0
February 14, 2023	SC 13G/A	CTMX / CytomX Therapeutics Inc / TANG CAPITAL PARTNERS LP - AMENDMENT NO. 1 Passive Investment SC 13G/A 1 ctmx28230sc13ga1.htm AMENDMENT NO. 1 Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* CytomX Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 23284F105 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of This Statement) Chec
February 14, 2023	SC 13G/A	CTMX / CytomX Therapeutics Inc / RTW INVESTMENTS, LP - CYTOMX THERAPEUTICS, INC. Passive Investment SC 13G/A 1 p23-0547sc13ga.htm CYTOMX THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* CytomX Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 23284F105 (CUSIP Number) December 31, 2022 (Date of event which requires filing of this state
February 9, 2023	SC 13G/A	CTMX / CytomX Therapeutics Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0703-cytomxtherapeuticsinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: CytomX Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 23284F105 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box t
January 5, 2023	8-K	Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2022 CYTOMX THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37587 27-3521219 (State or Other Jurisdiction of Incorporation) (Commis
November 22, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2022 CYTOMX THERAPEU UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2022 CYTOMX THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37587 27-3521219 (State or Other Jurisdiction of Incorporation) (Commis
November 8, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 08, 2022 CytomX Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37587 27-3521219 (State or Other Jurisdiction of Incorporation) (Commis
November 8, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37587 CytomX Therapeutics, Inc. (Exact name of
November 8, 2022	EX-10.3	Separation Agreement effective as of September 30, 2022, by and between CytomX Therapeutics, Inc. and Carlos Campoy. Exhibit 10.3 September 30 Carlos Campoy [***] Re: Employment Separation Dear Carlos: This letter (the "Agreement") confirms the terms of the offer made to you by CytomX Therapeutics, Inc. (the ?Company?) regarding the separation of your employment, effective as of September 30, 2022 (the ?Separation Date?) as a result of a reduction in force. If you sign and return this letter to me on or before N
November 8, 2022	EX-10.1	Consulting Agreement effective as of October 1, 2022, by and between CytomX Therapeutics, Inc. and Carlos Campoy. Exhibit 10.1 MASTER CONSULTING AGREEMENT This Consulting Agreement (the ?MCA?) is made and entered into by and between CytomX Therapeutics, Inc., a Delaware corporation, with an address at 151 Oyster Point Blvd, Suite 400, South San Francisco, CA 94080, (?Company?) and Carlos Campoy, located at [***] (?Consultant?), effective as of October 1, 2022 (?Effective Date?). Recitals Whereas, Consultant h
November 8, 2022	EX-10.5	Separation Agreement effective as of September 30, 2022, by and between CytomX Therapeutics, Inc. and Alison Hannah, M.D. Exhibit 10.5 September 30, 2022 Alison Hannah, M.D. [***] Re: Employment Separation Dear Alison: This letter (the "Agreement") confirms the terms of the offer made to you by CytomX Therapeutics, Inc. (the ?Company?) regarding the separation of your employment, effective as of September 30, 2022 (the ?Separation Date?) as a result of a reduction in force. If you sign and return this letter to me on
November 8, 2022	EX-99.1	CytomX Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update - Advancing wholly owned, next-generation conditionally activated therapeutics CX-2051 (EpCAM-directed ADC) and CX-801 (Interferon alpha-2b), with INDs anti Exhibit 99.1 CytomX Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update - Advancing wholly owned, next-generation conditionally activated therapeutics CX-2051 (EpCAM-directed ADC) and CX-801 (Interferon alpha-2b), with INDs anticipated in 2023 - - CX-904, Company?s first clinical stage Probody T-cell bispecific (EFGRxCD3), continues to advance in Phase 1 dose esc
November 8, 2022	EX-10.2	Consulting Agreement effective as of September 13, 2022, by and between CytomX Therapeutics, Inc. and Amy C. Peterson, M.D. Exhibit 10.2 MASTER CONSULTING AGREEMENT This Consulting Agreement (the ?MCA?) is made and entered into by and between CytomX Therapeutics, Inc., a Delaware corporation, with an address at 151 Oyster Point Blvd, Suite 400, South San Francisco, CA 94080, (?Company?) and Dr. Amy Peterson, located at [***] (?Consultant?), effective as of September 13, 2022 (?Effective Date?). Recitals Whereas, Consul
November 8, 2022	EX-10.4	Separation Agreement effective as of September 12, 2022, by and between CytomX Therapeutics, Inc. and Amy C. Peterson, M.D. Exhibit 10.4 September 12, 2022 Amy C. Peterson, M.D. [***] Re: Employment Separation Dear Amy: This letter (the "Agreement") confirms the terms of the offer made to you by CytomX Therapeutics, Inc. (the ?Company?) regarding the separation of your employment, effective as of September 12, 2022 (the ?Separation Date?) as a result of a reduction in force. If you sign and return this letter to me on
November 8, 2022	EX-10.6	Amendment No 3 to Collaboration and License Agreement, dated May 23, 2014, by and between the Company and Bristol Myers Squibb Company, effective as of October 11, 2022. Exhibit 10.6 AMENDMENT NO 3 TO COLLABORATION AND LICENSE AGREEMENT This Amendment Number 3 (the ?Amendment?), effective as of October 11, 2022 (the ?Amendment No 3 Effective Date?) amends that certain Collaboration and License Agreement entered into as of May 23, 2014 by and between CYTOMX THERAPEUTICS, INC., a corporation organized under the laws of the State of Delaware, having its principal pla
September 23, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 21, 2022 CYTOMX THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37587 27-3521219 (State or Other Jurisdiction of Incorporation) (Commi
September 13, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 8, 2022 CYTOMX THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37587 27-3521219 (State or Other Jurisdiction of Incorporation) (Commis
August 4, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37587 CytomX Therapeutics, Inc. (Exact name of Regi
August 4, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 04, 2022 CytomX Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37587 27-3521219 (State or Other Jurisdiction of Incorporation) (Commissi
August 4, 2022	EX-99.1	CytomX Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update - Recently-announced company restructuring focuses internal efforts on wholly-owned next-generation conditionally activated therapeutics, extending cash ru Exhibit 99.1 CytomX Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update - Recently-announced company restructuring focuses internal efforts on wholly-owned next-generation conditionally activated therapeutics, extending cash runway to 2025 - - New INDs for two next-generation product candidates anticipated in 2023 - - Continued progress with partnered clinical p
July 29, 2022	SC 13G/A	CTMX / CytomX Therapeutics Inc / BIOTECHNOLOGY VALUE FUND L P - AMENDMENT NO. 1 TO THE SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 CytomX Therapeutics, Inc. (Name of Issuer) Common Stock, $0.00001 par value per share (Title of Class of Securities) 23284F105 (CUSIP Numb
July 25, 2022	SC 13G	CTMX / CytomX Therapeutics Inc / TANG CAPITAL PARTNERS LP Passive Investment Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
July 25, 2022	EX-99.1	JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, $0.00001 par value per share, of CytomX Therapeutics, Inc. and further agree to the filing of this Joint Filing Agreement a
July 13, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Costs Associated with Exit or Disposal Activities UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 13, 2022 CYTOMX THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37587 27-3521219 (State or Other Jurisdiction of Incorporation) (Commission
July 6, 2022	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 6, 2022 CYTOMX THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37587 27-3521219 (State or Other Jurisdiction of Incorporation) (Commission
June 21, 2022	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2022 CYTOMX THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37587 27-3521219 (State or Other Jurisdiction of Incorporation) (Commission
May 5, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 05, 2022 CytomX Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37587 27-3521219 (State or Other Jurisdiction of Incorporation) (Commission
May 5, 2022	EX-99.1	CytomX Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update - Patient enrollment completed in Arm A in the Phase 2 study of praluzatamab ravtansine in breast cancer, initial data for both Arms A and B on track for se Exhibit 99.1 CytomX Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update - Patient enrollment completed in Arm A in the Phase 2 study of praluzatamab ravtansine in breast cancer, initial data for both Arms A and B on track for second half of 2022 - - Phase 2 expansion study of CX-2029 ongoing, patient enrollment completed for squamous non-small cell lung cancer co
May 5, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37587 CytomX Therapeutics, Inc. (Exact name of Reg
April 27, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? ? ? Filed by a Party other than the Registrant ?? Check the appropriate box: ???Preliminary Proxy Statement ???Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
April 27, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? ? ? Filed by a Party other than the Registrant ?? Check the appropriate box: ???Preliminary Proxy Statement ???Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ??Definitive Prox
April 14, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2022 CYTOMX THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37587 27-3521219 (State or Other Jurisdiction of Incorporation) (Commissio
March 23, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2022 CYTOMX THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37587 27-3521219 (State or Other Jurisdiction of Incorporation) (Commissio
March 4, 2022	S-8	As filed with the Securities and Exchange Commission on March 4, 2022 As filed with the Securities and Exchange Commission on March 4, 2022 Registration No.
March 4, 2022	EX-FILING FEES	Calculation of Filing Fee Tables 424b5 (Form Type) CytomX Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Exhibit 107 Calculation of Filing Fee Tables 424b5 (Form Type) CytomX Therapeutics, Inc.
March 4, 2022	424B5	Up to $63,296,000 Common Stock 424B5 1 d298487d424b5.htm FORM 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-258510 PROSPECTUS SUPPLEMENT (To prospectus dated August 18, 2021) Up to $63,296,000 Common Stock We previously entered into an Open Market Sale AgreementSM, or the sales agreement, with Jefferies LLC, or Jefferies, on February 27, 2020, relating to shares of our common stock, par value $0.
March 4, 2022	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) CytomX Therapeutics, Inc.
March 1, 2022	EX-10.20	Amendment No. 2 to the Collaboration and License Agreement, dated as of October 27, 2021, by and between CytomX Therapeutics, Inc. and Amgen, Inc. DocuSign Envelope ID: BC0B85A8-4C4E-49BF-9DC2-0D8965BBCF25 Exhibit 10.20 AMENDMENT NO. 2 TO THE COLLABORATION AND LICENSE AGREEMENT This Amendment No. 2 to the Collaboration Agreement (this ?Amendment?) is effective as of the 27th day of October, 2021 (the ?Amendment Effective Date?) by and between Amgen Inc., a Delaware corporation having an address at One Amgen Center Drive, Thousand Oaks, Calif
March 1, 2022	EX-10.3	Form of 2015 Plan Restricted Share Unit Award Grant Notice and Agreement Exhibit 10.3 CYTOMX THERAPEUTICS, INC. 2015 EQUITY INCENTIVE PLAN RESTRICTED SHARE UNIT AWARD GRANT NOTICE CytomX Therapeutics, Inc., a Delaware corporation, (the ?Company?), pursuant to its 2015 Equity Incentive Plan, as may be amended from time to time (the ?Plan?), hereby grants to the holder listed below (?Participant?), an award of restricted share units (?Restricted Share Units? or ?RSUs?).
March 1, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 01, 2022 CytomX Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37587 27-3521219 (State or Other Jurisdiction of Incorporation) (Commissio
March 1, 2022	EX-99.1	CytomX Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results, and Provides Business Update - Encouraging activity for CX-2029 in Phase 2 expansion study in squamous non-small cell lung cancer (sqNSCLC) reported in 2021 - - First-in Exhibit 99.1 CytomX Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results, and Provides Business Update - Encouraging activity for CX-2029 in Phase 2 expansion study in squamous non-small cell lung cancer (sqNSCLC) reported in 2021 - - First-in-human study of CX-904 in advanced solid tumors to be initiated in first half of 2022 - - Initial data for Arms A and B in Phase 2 study
March 1, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37587 CytomX Therapeu
February 14, 2022	SC 13G/A	CTMX / CytomX Therapeutics Inc / RTW INVESTMENTS, LP - CYTOMX THERAPEUTICS, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* CytomX Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 23284F105 (CUSIP Number) December 31, 2021 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pu
February 14, 2022	SC 13G/A	CTMX / CytomX Therapeutics Inc / RA CAPITAL MANAGEMENT, L.P. - CYTOMX THERAPEUTICS, INC. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* CYTOMX THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 23284F105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designa
February 14, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2022 CYTOMX THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37587 27-3521219 (State or Other Jurisdiction of Incorporation) (Commis
February 14, 2022	SC 13G/A	CTMX / CytomX Therapeutics Inc / Point72 Asset Management, L.P. - SCHEDULE 13G (AMENDMENT NO. 2) Passive Investment 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* (Name of Issuer) CytomX Therapeutics, Inc. (Title of Class of Securities) Common Stock, $0.00001 Par V
February 9, 2022	SC 13G/A	CTMX / CytomX Therapeutics Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: CytomX Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 23284F105 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is fil
February 7, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2022 CYTOMX THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37587 27-3521219 (State or Other Jurisdiction of Incorporation) (Commiss
February 1, 2022	SC 13G/A	CTMX / CytomX Therapeutics Inc / VICTORY CAPITAL MANAGEMENT INC Passive Investment SC 13G/A 1 cytomx13ga2123121.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* CYTOMX THERAPEUTICS INC (Name of Issuer) Common Stock (Title of Class of Securities) 23284F105 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designat
January 10, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 CYTOMX THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37587 27-3521219 (State or Other Jurisdiction of Incorporation) (Commiss
January 10, 2022	EX-99.1	© 2022 CytomX Therapeutics, Inc. 40 th Annual J.P. Morgan Healthcare Conference Sean McCarthy, D.Phil. President, Chief Executive Officer, and Chairman January 12, 2022 © 2022 CytomX Therapeutics, Inc. Destroying Cancer. Differently. CD3 EGFR CytomX Exhibit 99.1 ? 2022 CytomX Therapeutics, Inc. 40 th Annual J.P. Morgan Healthcare Conference Sean McCarthy, D.Phil. President, Chief Executive Officer, and Chairman January 12, 2022 Forward - Looking Statements This presentation may contain projections and other forward - looking statements regarding future events. All statements other tha n statements of historical facts contained in this present
January 3, 2022	SC 13G	CTMX / CytomX Therapeutics Inc / BIOTECHNOLOGY VALUE FUND L P Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 CytomX Therapeutics, Inc. (Name of Issuer) Common Stock, $0.00001 par value per share (Title of Class of Securities) 23284F105 (CUSIP Numbe
January 3, 2022	EX-99.1	Joint Filing Agreement Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated January 3, 2022 with respect to the Common Stock, $0.00001 par value per share of CytomX Therapeutics, Inc., a Delaware corporation, and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance
December 8, 2021	EX-1	Joint Filing Statement Pursuant to Rule 13d-1(k)(1) Exhibit 1 Joint Filing Statement Pursuant to Rule 13d-1(k)(1) The undersigned hereby consent and agree to the joint filing of Schedule 13G under the Securities Exchange Act of 1934, as amended, with respect to the Common Stock, par value $0.
December 8, 2021	SC 13G	CTMX / CytomX Therapeutics Inc / RTW INVESTMENTS, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* CytomX Therapeutics, Inc.
November 4, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37587 CytomX Therapeutics, Inc. (Exact name of
November 4, 2021	EX-99.1	CytomX Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update -Initial data release from Phase 2 study of CX-2029 remains on track for fourth quarter 2021- -Initial data release from Phase 2 study of praluzatamab rav Exhibit 99.1 CytomX Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update -Initial data release from Phase 2 study of CX-2029 remains on track for fourth quarter 2021- -Initial data release from Phase 2 study of praluzatamab ravtansine (CX-2009) expected in 2022- SOUTH SAN FRANCISCO, Calif., November 4, 2021 ? CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in
November 4, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 04, 2021 CytomX Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37587 27-3521219 (State or Other Jurisdiction of Incorporation) (Commis
October 4, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 29, 2021 CYTOMX THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37587 27-3521219 (State or Other Jurisdiction of Incorporation) (Commi
August 17, 2021	S-3/A	As filed with the Securities and Exchange Commission on August 16, 2021 Table of Contents As filed with the Securities and Exchange Commission on August 16, 2021 Registration No.
August 16, 2021	CORRESP	CytomX Therapeutics, Inc. 151 Oyster Point Blvd., Suite 400 South San Francisco, CA 94080 CytomX Therapeutics, Inc. 151 Oyster Point Blvd., Suite 400 South San Francisco, CA 94080 August 16, 2021 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Deanna Virginio Re: CytomX Therapeutics, Inc. Registration Statement on Form S-3 (Registration No. 333-258510) Ladies and Gentlemen: In accordance with Rule 461 of Re
August 12, 2021	LETTER	LETTER United States securities and exchange commission logo August 12, 2021 Sean A. McCarthy, D.Phil. President and Chief Executive Officer CytomX Therapeutics, Inc. 151 Oyster Point Blvd., Suite 400 South San Francisco, CA 94080 Re: CytomX Therapeutics, Inc. Registration Statement on Form S-3 Filed August 5, 2021 File No. 333-258510 Dear Dr. McCarthy: This is to advise you that we have not reviewed and
August 5, 2021	EX-4.4	Form of Indenture. Exhibit 4.4 CytomX Therapeutics, Inc. INDENTURE Dated as of , 20 [ ] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions. 1 Section 1.2. Other Definitions. 4 Section 1.3. Incorporation by Reference of Trust Indenture Act. 5 Section 1.4. Rules of Construction. 5 ARTICLE II. THE SECURITIES 5 Section 2.1. Issuable in Series. 5 Section 2.2. E
August 5, 2021	EX-99.1	CytomX Therapeutics Announces Second Quarter 2021 Financial Results and Provides Business Update Exhibit 99.1 CytomX Therapeutics Announces Second Quarter 2021 Financial Results and Provides Business Update SOUTH SAN FRANCISCO, Calif., August 5, 2021 ? CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated therapeutics based on its Probody? technology platform, today reported sec
August 5, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37587 CytomX Therapeutics, Inc. (Exact name of Regi
August 5, 2021	S-3	Powers of Attorney (incorporated by reference to the signature page hereto). Table of Contents As filed with the Securities and Exchange Commission on August 5, 2021 Registration No.
August 5, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 05, 2021 CytomX Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37587 27-3521219 (State or Other Jurisdiction of Incorporation) (Commissi
June 22, 2021	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2021 CYTOMX THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37587 27-3521219 (State or Other Jurisdiction of Incorporation) (Commission
May 6, 2021	10-Q	Quarterly Report - 10-Q - Q1/2021 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37587 CytomX Therapeutics, Inc. (Exact name of Reg
May 6, 2021	EX-99.1	CytomX Therapeutics Announces First Quarter 2021 Financial Results and Provides Business Update Exhibit 99.1 CytomX Therapeutics Announces First Quarter 2021 Financial Results and Provides Business Update SOUTH SAN FRANCISCO, Calif., May 6, 2021 ? CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated therapeutics based on its Probody? technology platform, today reported first q
May 6, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2021 CYTOMX THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37587 27-3521219 (State or Other Jurisdiction of Incorporation) (Commission F
May 6, 2021	EX-10.2	Amendment No 2 to Collaboration and License Agreement, as amended, dated March 17, 2017, by and between the Company and Bristol Myers Squibb, effective as of February 22, 2021. [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10).
May 6, 2021	EX-10.3	Consulting Agreement, effective as of April 1, 2021, by and between CytomX Therapeutics, Inc. and Dr. Charles Fuchs. EX-10.3 3 ctmx-ex103136.htm EX-10.3 - FUCHS CONSULTING AGREEMENT Exhibit 10.3 BUSINESS CONSULTING AGREEMENT This Consulting Agreement (the “Agreement”) is made and entered into by and between CytomX Therapeutics, Inc., a Delaware corporation, with an address at 151 Oyster Point Blvd, Suite 400, South San Francisco, CA 94080, (“Company”) and, Charles Fuchs, M.D., M.P.H., an individual residing at t
May 6, 2021	S-8	- S-8 As filed with the Securities and Exchange Commission on May 6, 2021 Registration No.
May 3, 2021	SC 13G/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 3)1 CytomX Therapeutics, Inc. (Name of Issuer) Common Stock, $0.00001 par value per share (Title of Class of Securities) 23284F105 (CUSIP Numb
April 28, 2021	DEF 14A	- DEF 14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? ? ? Filed by a Party other than the Registrant ?? Check the appropriate box: ???Preliminary Proxy Statement ???Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
April 28, 2021	DEFA14A	- DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? ? ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy S
March 4, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2021 CYTOMX THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37587 27-3521219 (State or Other Jurisdiction of Incorporation) (Commis
February 24, 2021	EX-10.25	Retirement Agreement by and between CytomX Therapeutics, Inc and Dr. W. Michael Kavanaugh, dated as of December 1, 2020. Exhibit 10.25 RETIREMENT AGREEMENT This Retirement Agreement (the ?Agreement?) by and between W. Michael Kavanaugh, M.D. (?Executive?), and CytomX Therapeutics, Inc., a Delaware corporation (the ?Company?), is made effective as of the twenty-fourth day following the date Executive signs this Agreement if not revoked in accordance with Section 5(c)(iii) (the ?Effective Date?) with reference to the
February 24, 2021	10-K	Annual Report - 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37587 CytomX Therapeu
February 24, 2021	EX-99.1	CytomX Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update -Broad advancement of clinical pipeline- -Three-arm Phase 2 study of praluzatamab ravtansine (CX-2009) launched in breast cancer- -Enrollme Exhibit 99.1 CytomX Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update -Broad advancement of clinical pipeline- -Three-arm Phase 2 study of praluzatamab ravtansine (CX-2009) launched in breast cancer- -Enrollment continues in Phase 2 expansion study of CX-2029 in four cancer types, in partnership with AbbVie- -Bristol Myers Squibb expands anti-C
February 24, 2021	S-8	Form S-8 As filed with the Securities and Exchange Commission on February 24, 2021 Registration No.
February 24, 2021	EX-10.24	Consulting Agreement effective as of December 14, 2020, by and between CytomX Therapeutics, Inc and Dr. W. Michael Kavanaugh. Exhibit 10.24 Certain identified information has been excluded from this exhibit because it is, both, not material, and would likely cause competitive harm to CytomX Therapeutics, Inc. if publicly disclosed. CONSULTING AGREEMENT This Consulting Agreement (the ?Agreement?) is made and entered into by and between CytomX Therapeutics, Inc., a Delaware corporation, with an address at 151 Oyster Point
February 24, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2021 CYTOMX THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37587 27-3521219 (State or Other Jurisdiction of Incorporation) (Commis
February 16, 2021	SC 13G/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* CytomX Therapeutics, Inc. (Name of Issuer) Common Stock, $0.00001 par value (Title of Class of Securit SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* CytomX Therapeutics, Inc. (Name of Issuer) Common Stock, $0.00001 par value (Title of Class of Securities) 23284F 10 5 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design
February 16, 2021	EX-99.1	AGREEMENT EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: February 16, 2021 PERCEPTIVE ADVISORS LLC
February 11, 2021	SC 13G/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2)1 CytomX Therapeutics, Inc. (Name of Issuer) Common Stock, $0.00001 par value per share (Title of Class of Securities) 23284F105 (CUSIP Numb
February 10, 2021	SC 13G/A	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: CytomX Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 23284F105 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is fil
February 2, 2021	SC 13G/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* CYTOMX THERAPEUTICS INC (Name of Issuer) Common Stock (Title of Class of Securities) (CUSIP Number) Dece UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* CYTOMX THERAPEUTICS INC (Name of Issuer) Common Stock (Title of Class of Securities) 23284F105 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this
January 29, 2021	EX-1	AGREEMENT EX-1 2 tm214667d1ex-1.htm EXHIBIT 1 EXHIBIT 1 AGREEMENT This Joint Filing Agreement, dated as of January 29, 2021, is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”). Each of the Filers may be required to file with the United States Securities and Exchange Commission a
January 29, 2021	SC 13G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* CYTOMX THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* CYTOMX THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 23284F105 (CUSIP Number) January 25 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th
January 26, 2021	EX-99.1	JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessi
January 26, 2021	SC 13G	CUSIP No. 23284F105 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.)* (Name of Issuer) CytomX Therapeutics, Inc. (Title of Class of Securities) Common Stock, $0.00001 Par Val
January 25, 2021	EX-1.1	Underwriting Agreement, dated as of January 20, 2021, among CytomX Therapeutics, Inc. and J.P Morgan securities LLC, Cowen and Company, LLC and Piper Sandler & Co., as representatives of the underwriters named therein. EX-1.1 Exhibit 1.1 CytomX Therapeutics, Inc. 14,285,714 Shares of Common Stock $0.00001 par value Underwriting Agreement January 20, 2021 J.P. Morgan Securities LLC Cowen and Company, LLC Piper Sandler & Co. As representatives (the “Representatives”) of the several Underwriters named in Schedule I hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Cowen and Compa
January 25, 2021	8-K	Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 20, 2021 CYTOMX THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37587 27-3521219 (State or Other Jurisdiction of Incorporation) (Commiss
January 21, 2021	424B5	CytomX Therapeutics, Inc. 151 Oyster Point Blvd., Suite 400 South San Francisco, CA 94080 (650) 515-3185 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Statement No.
January 19, 2021	424B5	CytomX Therapeutics, Inc. 151 Oyster Point Blvd., Suite 400 South San Francisco, CA 94080 (650) 515-3185 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Statement No.
January 19, 2021	8-K	Results of Operations and Financial Condition, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 19, 2021 CYTOMX THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37587 27-3521219 (State or Other Jurisdiction of Incorporation) (Commiss
December 22, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2020 CYTOMX THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37587 27-3521219 (State or Other Jurisdiction of Incorporation) (Commis
November 10, 2020	SC 13G/A	CTMX / CytomX Therapeutics, Inc. / BIOTECHNOLOGY VALUE FUND L P - AMENDMENT NO. 1 TO THE SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 CytomX Therapeutics, Inc. (Name of Issuer) Common Stock, $0.00001 par value per share (Title of Class of Securities) 23284F105 (CUSIP Numb
November 5, 2020	EX-10.3	Amendment No. 1 to the Collaboration and License Agreement, dated as of September 29, 2020, by and between CytomX Therapeutics, Inc. and Amgen, Inc. [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10).
November 5, 2020	EX-99.1	CytomX Therapeutics Announces Third Quarter 2020 Financial Results and Provides Business Update Company to host a conference call today, November 5, 2020, at 5:00 p.m. ET / 2:00 p.m. PT Exhibit 99.1 CytomX Therapeutics Announces Third Quarter 2020 Financial Results and Provides Business Update Company to host a conference call today, November 5, 2020, at 5:00 p.m. ET / 2:00 p.m. PT SOUTH SAN FRANCISCO, CA, November 5, 2020– CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody the
November 5, 2020	10-Q	Quarterly Report - 10-Q Q3/2020 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37587 CytomX Therapeutics, Inc. (Exact name of
November 5, 2020	EX-10.1	Research Collaboration, Option and License Agreement dated as of May 30, 2013, by and between CytomX Therapeutics, Inc. and Pfizer, Inc. Exhibit 10.1 FOIA CONFIDENTIAL TREATMENT GRANTED research collaboration, OPTION and LICENSE AGREEMENT by and between Pfizer Inc. and CytomX Therapeutics, Inc. May 30, 2013 ***Certain information contained herein has been omitted pursuant to Regulation S-K 601(b)(10). Confidential treatment has been granted with respect to the omitted portions. TABLE OF CONTENTS Page 1. DEFINITIONS. 1 2. RESEARCH P
November 5, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K - Q3-20 EARNINGS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2020 CYTOMX THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37587 27-3521219 (State or Other Jurisdiction of Incorporation) (Commiss
November 5, 2020	EX-10.2	Collaboration and License Agreement dated as of May 23, 2014, by and between CytomX Therapeutics, Inc. and Bristol Myers Squibb Company. Exhibit 10.2 FOIA CONFIDENTIAL TREATMENT GRANTED COLLABORATION AND LICENSE AGREEMENT THIS COLLABORATION AND LICENSE AGREEMENT (the “Agreement”) is made and entered into as of May 23, 2014 (the “Execution Date”) by and between CYTOMX THERAPEUTICS, INC., a corporation organized under the laws of the State of Delaware, having its principal place of business at 343 Oyster Point Blvd., Suite 100, South
October 6, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 6, 2020 CYTOMX THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37587 27-3521219 (State or Other Jurisdiction of Incorporation) (Commissi
August 6, 2020	EX-4.4	Description of Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934. Exhibit 4.4 DESCRIPTION OF REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following summary describes the capital stock of CytomX Therapeutics, Inc. (the “Company,” “we,” “us,” and “our”) and the material provisions of our amended and restated certificate of incorporation and our amended and restated bylaws, the registration rights agreement to
August 6, 2020	10-Q	Quarterly Report - 10-Q - Q2/2020 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37587 CytomX Therapeutics, Inc. (Exact name of Regi
August 6, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2020 CYTOMX THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37587 27-3521219 (State or Other Jurisdiction of Incorporation) (Commissio
August 6, 2020	EX-99.1	CytomX Therapeutics Announces Second Quarter 2020 Financial Results and Provides Business Update Company to Host a Conference Call Today, August 6, 2020, at 5:30 p.m. ET / 2:30 p.m. PT Exhibit 99.1 CytomX Therapeutics Announces Second Quarter 2020 Financial Results and Provides Business Update Company to Host a Conference Call Today, August 6, 2020, at 5:30 p.m. ET / 2:30 p.m. PT SOUTH SAN FRANCISCO, CA, August 6, 2020– CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therap
June 23, 2020	EX-3.1	Certificate of Amendment to Amended and Restated Certificate of Incorporation of CytomX Therapeutics, Inc. EX-3.1 Exhibit 3.1 CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CYTOMX THERAPEUTICS, INC. (a Delaware corporation) (Pursuant to Section 242 of the General Corporation Law of the State of Delaware) CytomX Therapeutics, Inc., a corporation organized and existing under the General Corporation Law of the State of Delaware as set forth in Title 8 of the Delaware Code
June 23, 2020	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2020 CYTOMX THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37587 27-3521219 (State or Other Jurisdiction of Incorporation) (Commission
May 29, 2020	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2020 CYTOMX THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37587 27-3521219 (State or Other Jurisdiction of Incorporation) (Commission
May 7, 2020	EX-99.1	CytomX Therapeutics Announces First Quarter 2020 Financial Results and Provides Business Update Company to Host a Conference Call Today, May 7, 2020, at 5:00 p.m. ET / 2:00 p.m. PT Exhibit 99.1 CytomX Therapeutics Announces First Quarter 2020 Financial Results and Provides Business Update Company to Host a Conference Call Today, May 7, 2020, at 5:00 p.m. ET / 2:00 p.m. PT SOUTH SAN FRANCISCO, CA, May 7, 2020– CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics
May 7, 2020	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37587 CytomX Therapeutics, Inc. (Exact name of Reg
May 7, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2020 CYTOMX THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37587 27-3521219 (State or Other Jurisdiction of Incorporation) (Commission F
May 7, 2020	EX-10.4	Collaboration and License Agreement dated as of March 23, 2020, by and between CytomX Therapeutics, Inc. and Astellas Pharma Inc. Exhibit 10.4 COLLABORATION AND LICENSE AGREEMENT by and between CYTOMX THERAPEUTICS, inc. and ASTELLAS PHARMA INC. Dated as of March 23, 2020 COLLABORATION AND LICENSE AGREEMENT This Collaboration and License Agreement (“Agreement”) is entered into as of March 23, 2020 (the “Effective Date”) by and between CytomX Therapeutics, Inc., organized and existing under the laws of Delaware with its princi
May 7, 2020	EX-10.1	Severance and Change of Control Agreement dated March 23, 2020, by and between CytomX Therapeutics, Inc. and Carlos Campoy. Exhibit 10.1 Amended and Restated Severance and Change of Control Agreement This Amended and Restated Severance and Change of Control Agreement (the “Agreement”) is made and entered into, effective as of March 23, 2020 (the “Effective Date”), by and between CytomX Therapeutics, Inc. a Delaware corporation (the “Company”), and Carlos Campoy (“Employee”). Upon acceptance of this Agreement, the follo
May 7, 2020	EX-10.3	Employment Offer Letter Agreement between CytomX Therapeutics, Inc. and Carlos Campoy dated as of March 9, 2020. Exhibit 10.3 DELIVERED VIA DOCUSIGN March 9, 2020 Carlos Campoy [email protected] Dear Carlos, On behalf of Cytomx Therapeutics (“CytomX” or the “Company”), I am pleased to offer you an exempt position of Senior Vice President, Chief Financial Officer, reporting directly to me. Total Rewards: Compensation Your base salary will be paid at the rate of $38,750.00 per month ($465,000.00 annualized) l
April 29, 2020	DEFA14A	- DEFA 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Stat
April 29, 2020	TEXT-EXTRACT	- United States securities and exchange commission logo April 29, 2020 Lloyd Rowland, Esq.
April 29, 2020	DEF 14A	Schedule 14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ D
April 29, 2020	LETTER	LETTER United States securities and exchange commission logo April 29, 2020 Lloyd Rowland, Esq.
April 28, 2020	CORRESP	- CORRESP 505 Montgomery Street, Suite 2000 San Francisco, California 94111-6538 Tel: +1.
April 28, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2020 CYTOMX THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37587 27-3521219 (State or Other Jurisdiction of Incorporation) (Commissio
April 17, 2020	PRE 14A	CTMX / CytomX Therapeutics, Inc. PRE 14A - - PRE 14A PRE 14A 1 nc10011036x1pre14a.htm PRE 14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Onl
March 30, 2020	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2020 CYTOMX THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37587 27-3521219 (State or Other Jurisdiction of Incorporation) (Commissio
March 24, 2020	8-K	Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2020 CYTOMX THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37587 27-3521219 (State or Other Jurisdiction of Incorporation) (Commissio
March 23, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2020 CYTOMX THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37587 27-3521219 (State or Other Jurisdiction of Incorporation) (Commissio
March 6, 2020	SC 13G	CTMX / CytomX Therapeutics, Inc. / Biotechnology Value Fund L P - THE SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 CytomX Therapeutics, Inc. (Name of Issuer) Common Stock, $0.00001 par value (Title of Class of Securities) 23284F105 (CUSIP Number) Februar
March 6, 2020	EX-99.1	Joint Filing Agreement Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated March 6, 2020 with respect to the shares of Common Stock of CytomX Therapeutics, Inc., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under
March 6, 2020	EX-99.1	Joint Filing Agreement Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated March 6, 2020 with respect to the shares of Common Stock of CytomX Therapeutics, Inc., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under
March 6, 2020	EX-99.1	Joint Filing Agreement Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated March 6, 2020 with respect to the shares of Common Stock of CytomX Therapeutics, Inc., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under
March 6, 2020	EX-99.1	Joint Filing Agreement Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated March 6, 2020 with respect to the shares of Common Stock of CytomX Therapeutics, Inc., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under
March 6, 2020	EX-99.1	Joint Filing Agreement Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated March 6, 2020 with respect to the shares of Common Stock of CytomX Therapeutics, Inc., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under
March 6, 2020	EX-99.1	Joint Filing Agreement Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated March 6, 2020 with respect to the shares of Common Stock of CytomX Therapeutics, Inc., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under
February 27, 2020	EX-10.32	Severance and Change of Control Agreement effective as of February 3, 2020, by and between CytomX Therapeutics, Inc. and Alison Hannah, M.D. Exhibit 10.32 Amended and Restated Severance and Change of Control Agreement This Amended and Restated Severance and Change of Control Agreement (the “Agreement”) is made and entered into, effective as of February 3, 2020 (the “Effective Date”), by and between CytomX Therapeutics, Inc. a Delaware corporation (the “Company”), and Alison Hannah, M.D. (“Employee”). Upon acceptance of this Agreement,
February 27, 2020	EX-99.1	CytomX Therapeutics Announces Full-Year 2019 Financial Results and Provides Business Update Company to Host a Conference Call Today, February 27, 2020, at 5:00 p.m. ET / 2:00 p.m. PT Exhibit 99.1 CytomX Therapeutics Announces Full-Year 2019 Financial Results and Provides Business Update Company to Host a Conference Call Today, February 27, 2020, at 5:00 p.m. ET / 2:00 p.m. PT SOUTH SAN FRANCISCO, CA, February 27, 2020– CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody thera

CTMX / CytomX Therapeutics, Inc. - Документы SEC, Годовой отчет, Доверенное заявление

Основная статистика

SEC Filings

SEC Filings (Chronological Order)

Other Listings